egrifta sv
(tesamorelin)Theratechnologies Inc.
Usage: EGRIFTA SV is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not intended for weight loss management, and long-term cardiovascular safety is unestablished. Treatment continuation should be reconsidered if there is no reduction in visceral adipose tissue.